GSEA suggested that AKT pathway is up-regulated in MDS patients harboring ASXL1 mutations, but not those harboring DNMT3A or TET2 mutations, compared to healthy control subjects (Supplementary Table 2). The gene discussed is DNMT3A; the disease is myelodysplastic syndrome.